Genomic alterations of ERBB receptors in cancer: clinical implications

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• The ERBB (Epidermal Growth Factor Receptor) family of receptor tyrosine kinases, including EGFR, HER2, HER3, and HER4, plays a significant role in cancer.
• These receptors are involved in complex signaling networks that regulate cell growth and survival.
• Aberrant ERBB signaling, through amplification or mutation, is a hallmark of various cancers, notably gliomas, lung, breast, and gastric carcinomas.

Purpose of the Study:

• To review the landscape of genomic alterations across the ERBB family members (EGFR, HER2, HER3, HER4) in human cancers.
• To discuss the clinical implications of these alterations, including their potential as oncogenic drivers.
• To examine the emerging role of ERBB mutations in resistance to FDA-approved EGFR and HER2 inhibitors.

Main Methods:

• Comprehensive literature review of studies investigating ERBB family genomic alterations in cancer.
• Analysis of data from next-generation sequencing and large-scale genomic projects.
• Synthesis of findings related to clinical outcomes and therapeutic responses.

Main Results:

• Somatic mutations in ERBB receptors are observed at low frequencies across diverse tumor types.
• Specific ERBB alterations are well-established drivers in certain cancers (e.g., EGFR in gliomas, HER2 in breast cancer).
• Emerging evidence indicates that certain ERBB mutations can confer resistance to targeted therapies like EGFR and HER2 inhibitors.

Conclusions:

• Genomic alterations in the ERBB family are critical in cancer development and progression.
• Understanding these alterations is essential for predicting patient response to targeted therapies.
• Further research into ERBB mutations is needed to develop novel therapeutic strategies and overcome treatment resistance.